Clinical Trial ResultsThe open-label portion of HT-001 trial yields promising results, with 100% of patients achieving the primary efficacy endpoint, showing significant skin toxicity improvement.
Financial PerformanceHoth reported a net loss of $0.24 per share, which was narrower than the forecast for a net loss of $0.39 per share.
Patent And Intellectual PropertyThe company has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing rights to a groundbreaking innovation aimed at treating obesity and associated health conditions.